Fig. 2: AD GWAS loci annotation by ancestry and AD-related phenotypes.

a Nominal p-values (y-axis) derived from the multiple ancestry-combined (MULTI) (top panel) and the European-ancestry stratified (EUR) (bottom panel) GWAS meta-analysis are plotted by corresponding genomic coordinate (x-axis). P-values are derived from a two-sided test for effect size in a fixed-effect inverse variance weighted approach (Methods). Novel associations are highlighted in green and annotated with the nearest gene. Associations that reached significance (P < 5e−08) in both MULTI and EUR GWAS meta-analyses are annotated in the top panel; associations that reached significance (P < 5e−08) in only the EUR GWAS meta-analysis are annotated in the bottom panel. b Top panel illustrates the presence of significant (P < 5e−08) AD GWAS loci (x-axis) across ancestry-stratified and -combined GWAS meta-analyses (y-axis); significant loci per ancestry endpoint are indicated with a darker color shade. P-values are derived from a two-sided test for effect size in a fixed-effect inverse variance weighted approach (Methods). Bottom panel illustrates overlap of significant AD GWAS loci with previously reported genome-wide significant (P < 5e−08) and suggestive (P < 5e−06) GWAS loci for AD/eczema, allergy, and asthma phenotypes (Supplementary Data 10, 11). Bold frame indicates the 16 novel AD GWAS loci reported herein, annotated with corresponding cytoband, lead variant and nearest gene. P-values are shown as reported in the EBI GWAS Catalog (Methods).